Outline Immunocompetence and the effects of B-cell–directed therapies
{"Image DocumentName": "Outline Immunocompetence and the effects of B-cell\u2013directed therapies", "Image ImageDescription": "Safety of B-cell\u2013directed therapies. Long-term safety of repeated use. Effects on serum immunoglobulins. Serious infection rates. Safety of switching to DMARD or TNF inhibitor after RTX failure. Immunization and B-cell\u2013directed therapy. Considerations for immunocompetence of newer B-cell\u2013 targeting agents BAFF, APRIL. Progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. 53.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}